Acadia Pharmaceuticals Inc., of San Diego, presented data at the International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, from its Phase III program testing pimavanserin in Parkinson's disease psychosis (PDP), including data from the pivotal -020 study and related -015 open-label safety extension trial...Mei Pharma Inc., of San Diego, said the first patients were dosed in a Phase II trial of its lead candidate, HDAC inhibitor Pracinostat, in combination with Vidaza
Hemaquest Pharmaceuticals Inc., of San Diego, has completed enrollment in a randomized, double-blind, placebo-controlled Phase IIb study of HQK-1001 in patients with sickle cell disease
La Jolla Pharmaceutical Co., of San Diego, said it submitted an investigational new drug application for LJPC-501, a peptide agonist of the renin-angiotensin system, for the treatment of patients with Type I and Type II hepatorenal syndrome, a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure
Prometheus Laboratories Inc., of San Diego, said PROCLIVITY02, a study comparing the sequence of Proleukin (high dose interleukin-2), followed by Yervoy (ipilimumab, Bristol-Myers Squibb Co.) to the converse order, as therapy in patients with metastatic melanoma, has investigational review board approval and anticipates enrolling patients this summer
La Jolla Pharmaceutical Co., of San Diego, said data from a Phase I (Part A) portion of the Phase I/II trial of GCS-100 in patients with chronic kidney disease (CKD) showed no serious adverse events, and there were no adverse changes in laboratory measures
Sorrento Therapeutics Inc., of San Diego, and Igdrasol Inc., of Irvine, Calif., reported data showing that five out of 16 patients (31.3 percent) treated with Cynviloq at 300 mg/m2 every three weeks in combination with gemcitabine as a first-line treatment in advanced pancreatic cancer had confirmed complete or partial responses
La Jolla Pharmaceutical Co., of San Diego, released data detailing the ability of lead product candidate GCS-100 to improve renal function...Lpath Inc., of San Diego, began dosing in a Phase IIa trial of Asonep for renal cell carcinoma in patients that have failed standard VEGF- or mTOR-targeted treatments
Ceregene Inc., of San Diego, reported additional efficacy data from a secondary analysis of its Phase IIb study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin to treat Parkinson's disease
Elcelyx Therapeutics Inc., of San Diego, said it is enrolling patients with Type II diabetes in a Phase IIb trial of NewMet, a delayed-release formulation of generic metformin...Tracon Pharmaceuticals Inc., of San Diego, said it initiated two randomized Phase IIb studies to evaluate TRC105 in combination with bevacizumab (Avastin) in metastatic kidney cancer and recurrent glioblastoma multiforme
Prometheus Laboratories Inc., of San Diego, said PROCLIVITY 01, a multicenter study of Proleukin (High Dose Interleukin-2 [HD IL-2])1 plus vemurafenib therapy in patients with BRAF V600 mutation-positive metastatic melanoma (mM) is enrolling patients
Metreleptin was part of the alliance between BMS and AstraZeneca plc, of London, to buy out Amylin Pharmaceuticals Inc., of San Diego, which had metreleptin among its assets. (See BioWorld Today, July 5, 2012...La Jolla Pharmaceutical Co., of San Diego, treated the last patient in the Phase I (Part A) portion of the Phase I/II trial of GCS-100 in patients with chronic kidney disease (CKD
Halozyme Therapeutics Inc., of San Diego, initiated a Phase II trial evaluating PEGPH20 as a first-line therapy for patients with Stage IV metastatic pancreatic cancer
Ceregene Inc., of San Diego, reported top-line data from its double-blind, randomized, controlled Phase IIb study of CERE-120 (AAV-neurturin), a gene therapy designed to deliver the neurotrophic factor neurturin, for Parkinson's disease
Arena Pharmaceuticals Inc., of San Diego, initiated dosing in a Phase I trial of APD334, an oral drug candidate targeting the sphingosine 1-phosphate subtype 1 receptor, for the potential treatment of autoimmune diseases
Aragon Pharmaceuticals Inc., of San Diego, dosed its first patient in a Phase I trial of ARN-810 for estrogen receptor-positive breast cancer...Vital Therapies Inc., of San Diego, enrolled the first patient in a Phase III trial designated VTI-208, a randomized, open-label, multicenter, controlled trial comparing the company's investigational bio-artificial liver support system, ELAD plus standard of care, vs
Neurocrine Biosciences Inc., of San Diego, said it started a Phase IIb trial testing elagolix, an oral gonadotropin-releasing hormone antagonist, in uterine fibroids
OncoSec Medical Inc., of San Diego, reported positive, durable response results in an update on interim data from its Phase II metastatic melanoma trial of its ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors...Trius Therapeutics Inc., of San Diego, reported top-line results from its ESTABLISH 2 Phase III study of tedizolid phosphate (TR-701) in acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA
Upsher-Smith Laboratories Inc., of Maple Grove, Minn., presented data at the American Academy of Neurology meeting in San Diego, supporting favorable tolerability and a predictable, consistent pharmacokinetic profile of USL255 at high doses following single-dose administration to healthy subjects
Data were presented at the American Academy of Neurology meeting in San Diego...Data, presented at the American Academy of Neurology meeting in San Diego, indicated that Plegridy significantly reduced MS disease activity, including relapses, disability progression and brain lesions, compared to placebo at one year
Acadia Pharmaceuticals Inc., of San Diego, presented data at the International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, from its Phase III program testing pimavanserin in Parkinson's disease psychosis (PDP), including data from the pivotal -020 study and related -015 open-label safety extension trial...Mei Pharma Inc., of San Diego, said the first patients were dosed in a Phase II trial of its lead candidate, HDAC inhibitor Pracinostat, in combination with Vidaza